All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FX-322
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: FX-322
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
FX-322 is Frequency’s lead product candidate for the treatment of acquired SNHL. The Phase 2a study is a randomized, double blind, placebo-controlled, single- and repeat-dose study which enrolled 95 patients, aged 18 to 65, with stable SNHL.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FX-322
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: FX-322
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2020
Details:
New data build upon Phase 1/2 study results showed that for the first time, statistically significant improvements in word recognition (WR) scores in patients with chronic moderate to moderately severe SNHL.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mometasone Furoate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: LYR-210
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
Company will make presentations related to its lead product candidate, LYR-210, at the 66th Annual Meeting of the American Rhinologic Society (ARS), taking place as a virtual event.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Betahistine Dihydrochloride
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: AM-125
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
Interim analysis of Phase 2 “TRAVERS” trial demonstrated a dose-dependent improvement in balance as well as good safety and tolerability of ascending doses of AM-125.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Etokimab
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: ANB020
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
Etokimab q4w and q8w treatment arms failed to achieve NPS and SNOT-22 statistical significance over placebo at this week 8 interim analysis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Betahistine Dihydrochloride
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: AM-125
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020
Details:
Auris Medical Holding completed patient enrollment into Part A of its Phase 2 “TRAVERS” trial with intranasal betahistine in vertigo (AM-125). The Company expects to release interim results from TRAVERS and commence Part B of the trial in the coming weeks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LECITHIN API,Cholesteryl Palmitate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
Although the study did not achieve statistical significance for the primary efficacy endpoints, But the statistical trend were encouraging that favored the OP0201 treatment group with regard to resolution of middle ear effusion.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FX-322
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Study revealed measurable concentrations of FX-322 in every patient and that anatomical factors did not prevent the active agents of FX-322 from reaching the cochlea. The levels of FX-322 in the cochlea were predicted to reach the therapeutically active range of the treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mometasone Furoate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $58.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 09, 2020
Details:
The money will all go toward its ENT meds, which include LYR-210, a miniaturized, bioresorbable device that is implanted deep in the nasal passages.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LECITHIN API,Cholesteryl Palmitate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2020
Details:
Study is assessing the safety, tolerability, and efficacy of 20 mg/day intranasal OP0201 as an adjunct therapy to oral antibiotic treatment of acute otitis media in infants and 6 to 24 months olds.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
